E02.1 - Individualized splice-switching oligonucleotide therapy

Value of the Information & Strength of the Argument

The talk provides valuable insights into the current state and future directions of ASO therapy, particularly for rare diseases. The speaker effectively argues for the utility of splice-switching ASOs by presenting concrete examples, such as nusinersen for SMA and exon skipping for DMD, and by citing recent research on allele-specific silencing. The argumentation is solid, grounded in published studies and clinical data, though it is primarily an expert opinion rather than a systematic review. The speaker also highlights the importance of genetic data and collaborative networks, adding practical value for clinicians and researchers.

Scientific Rigor, Source Quality, Title Accuracy

The talk demonstrates scientific rigor by referencing FDA-approved drugs, key publications, and ongoing initiatives. The speaker mentions specific studies, such as the allele-specific silencing paper in Nature Medicine and the N1C variant selection guideline, and provides QR codes for further resources. The title accurately reflects the content, focusing on individualized splice-switching therapy. The presentation is well-structured and evidence-based, though it does not provide a comprehensive literature review. The speaker’s expertise and the inclusion of recent developments enhance the credibility of the content.

The title accurately reflects the content, which focuses on individualized splice-switching oligonucleotide therapy, covering mechanisms, clinical applications, and challenges.

8/10

Talk by an academic expert in the field of antisense oligonucleotide therapy, presenting established mechanisms and recent developments. The content is based on published research and FDA-approved drugs, but is presented as an expert overview rather than a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and disclosure
• 05:00Overview of FDA-approved antisense drugs
• 10:00Mechanism of gene silencing with gapmers
• 15:00Allele-specific silencing and recent publication
• 20:00Splice-switching: exon skipping for DMD
• 25:00Exon inclusion for SMA and nusinersen development
• 30:00Challenges: delivery and conjugation strategies
• 35:00Genetic data and variant selection guidelines
• 40:00UK Platform Nucleic Acid Therapy (UPNET) initiative
• 45:00Conclusion and future directions

• Nature Medicine paper on allele-specific silencing — Mentioned as published in August last year from Windy Trunks' group
• N1C collaborative consortium variant selection guideline — Mentioned as recently published and led by Malan Lawer from Netherlands
• Paper on antisense design from Anica (Netherlands) — Referenced as a 'bible' for ASO design

• FDA-approved antisense drugs — The speaker mentions 19 FDA-approved antisense drugs, which can be verified through FDA databases.
• Nusinersen approval — The speaker discusses nusinersen for SMA, which was FDA-approved in 2016.